Tomer Avni1, Shelley Reich2, Nirit Lev3, Anat Gafter-Gvili2. 1. Internal Medicine E, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel and Sackler Faculty of Medicine, Tel-Aviv University, Israel. Electronic address: tomerav@clalit.org.il. 2. Internal Medicine A, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel and Sackler faculty of Medicine, Tel-Aviv University, Israel. 3. Neurology Department, Meir Medical Center, Kfar Saba, Israel and Sackler Faculty of Medicine, Tel-Aviv University, Israel.
Abstract
BACKGROUND: Iron supplementation, is recommended for the treatment of restless legs syndrome (RLS). We gathered evidence for the efficacy and safety of iron supplementation for RLS. METHODS: A systematic review and meta-analysis of randomized controlled trials that compared iron supplementation versus no iron for patients with RLS was performed. Multiple databases were searched. The primary outcome was the effect of iron on the International Restless Legs Syndrome score (IRLSS) at 4 weeks after treatment. For dichotomous data, risk ratios (RR) with 95% confidence intervals (CIs) were estimated and pooled. For continuous data, weighted mean differences (WMD) were calculated. RESULTS: Ten trials fulfilled the inclusion criteria. Iron therapy was associated with a significant decrease of the IRLSS of -3.55 [95% CI (-5.41) - (-1.68)] points and an increase in the percentage of patients with improvement of the IRLSS score, RR of 2.16 [95% CI 1.56-2.98]. IV FCM was associated with improvement in both the IRLSS (WMD of -2.79 (95% CI (-4.62) - (-0.96), 4 trials, I2 = 0%) and on the RLS-QOL by WMD of 8.67 (95% CI 1.68-15). Iron was associated with an increased rate of adverse events RR 2.04 (95% CI 1.46-2.85), which were not severe and not associated with increased rate of treatment discontinuation. CONCLUSION: Iron supplementation is associated with improvement of the IRLSS score. Our meta-analysis supports the use of iron, oral or IV, as effective therapy for patients with RLS. Further studies should assess subgroups of patients most likely to benefit from iron supplementation.
BACKGROUND:Iron supplementation, is recommended for the treatment of restless legs syndrome (RLS). We gathered evidence for the efficacy and safety of iron supplementation for RLS. METHODS: A systematic review and meta-analysis of randomized controlled trials that compared iron supplementation versus no iron for patients with RLS was performed. Multiple databases were searched. The primary outcome was the effect of iron on the International Restless Legs Syndrome score (IRLSS) at 4 weeks after treatment. For dichotomous data, risk ratios (RR) with 95% confidence intervals (CIs) were estimated and pooled. For continuous data, weighted mean differences (WMD) were calculated. RESULTS: Ten trials fulfilled the inclusion criteria. Iron therapy was associated with a significant decrease of the IRLSS of -3.55 [95% CI (-5.41) - (-1.68)] points and an increase in the percentage of patients with improvement of the IRLSS score, RR of 2.16 [95% CI 1.56-2.98]. IV FCM was associated with improvement in both the IRLSS (WMD of -2.79 (95% CI (-4.62) - (-0.96), 4 trials, I2 = 0%) and on the RLS-QOL by WMD of 8.67 (95% CI 1.68-15). Iron was associated with an increased rate of adverse events RR 2.04 (95% CI 1.46-2.85), which were not severe and not associated with increased rate of treatment discontinuation. CONCLUSION:Iron supplementation is associated with improvement of the IRLSS score. Our meta-analysis supports the use of iron, oral or IV, as effective therapy for patients with RLS. Further studies should assess subgroups of patients most likely to benefit from iron supplementation.
Authors: Leonard B Weinstock; Arthur S Walters; Jill B Brook; Zahid Kaleem; Lawrence B Afrin; Gerhard J Molderings Journal: J Clin Sleep Med Date: 2020-01-14 Impact factor: 4.062
Authors: Vincent Beliveau; Ambra Stefani; Christoph Birkl; Christian Kremser; Elke R Gizewski; Birgit Högl; Christoph Scherfler Journal: Neuroimage Clin Date: 2022-04-26 Impact factor: 4.891
Authors: Shangru Lyu; Mark P DeAndrade; Stefan Mueller; Alexander Oksche; Arthur S Walters; Yuqing Li Journal: Behav Brain Res Date: 2019-07-31 Impact factor: 3.332
Authors: Giuseppe Didato; Roberta Di Giacomo; Giuseppa Jolanda Rosa; Ambra Dominese; Marco de Curtis; Paola Lanteri Journal: Int J Environ Res Public Health Date: 2020-05-22 Impact factor: 3.390
Authors: Jan Karregat; Maike G Sweegers; Franke A Quee; Henriëtte H Weekamp; Dorine W Swinkels; Vĕra M J Novotny; Hans L Zaaijer; Katja van den Hurk Journal: BMJ Open Date: 2022-03-09 Impact factor: 2.692